Stockreport

VistaGen Therapeutics Announces Positive Preclinical Data of AV-101 Combined with Probenecid Suggesting Substantially Increased Brain Concentration Effects

VistaGen Therapeutics, Inc.  (VTGN) 
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vistagen.com